Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591756 | 0.82 | LMNA (0.49) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL564192 | 0.80 | MEN1 (0.57) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL2186014 | 0.79 | ALDH1A1 (0.61) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL17198946 | 0.79 | LMNA (0.46) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL18624786 | 0.79 | LMNA (0.46) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL1360716 | 0.79 | THRB (0.54) | LMNAKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16216296 | 0.79 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL4100287 | 0.78 | IDO1 (0.52) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL20113982 | 0.78 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2KMT2AMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL30496708 | 0.77 | IDO1 (0.46) | LMNASMN1; SMN2KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067464-B2 | Compositions and methods using apocynin compounds and nitric oxide donors | NITROMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1603933-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005107384-A2 | METHODS FOR TREATING BLOOD DISORDERS WITH NITRIC OXIDE DONOR COMPOUNDS | NITROMED, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005070006-A2 | NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004098538-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | LMNA 2819/4885SMN1; SMN2 2070/4885KMT2A 4509/4885 |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | LMNA 3927/4885SMN1; SMN2 2553/4885KMT2A 3639/4885 |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | LMNA 2524/4885SMN1; SMN2 2146/4885KMT2A 3937/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | LMNA 2873/4885SMN1; SMN2 1781/4885KMT2A 4488/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | LMNA 615/4885SMN1; SMN2 3461/4885KMT2A 4596/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | LMNA 2524/4885SMN1; SMN2 2146/4885KMT2A 3937/4885 |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | ADRB3, GNAI3, GNB1 | LMNA 3721/4885SMN1; SMN2 2943/4885KMT2A 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.